Posts

Showing posts with the label Relapsed or Refractory Metastatic Colorectal Cancer competitive landscape

Relapsed or Refractory Metastatic Colorectal Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034

Relapsed or Refractory Metastatic Colorectal Cancer  Market Outlook Thelansis’s “Relapsed or Refractory Metastatic Colorectal Cancer   Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Relapsed or Refractory Metastatic Colorectal Cancer   treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Relapsed or Refractory Metastatic Colorectal Cancer   Overview Colorectal cancer (CRC) is the 3rd commonest cause of cancer death. Approximately 25% of patients have metastatic disease at diagnosis, and about 50%-60% of patients diagnosed with CRC further progressed to develop metastatic disease. Visceral obesity has been reported to...